$2.80
-0.05 (-1.75%)
Open$2.84
Previous Close$2.85
Day High$2.90
Day Low$2.73
52W High$5.46
52W Low$2.32
Volume—
Avg Volume242.8K
Market Cap91.37M
P/E Ratio—
EPS$-0.30
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+442.1% upside
Current
$2.80
$2.80
Target
$15.18
$15.18
$12.50
$15.18 avg
$18.81
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.06M | 11.02M | 11.79M |
| Net Income | 2.28M | 2.12M | 2.45M |
| Profit Margin | 18.9% | 19.3% | 20.8% |
| EBITDA | 3.37M | 3.22M | 3.75M |
| Free Cash Flow | 1.70M | 2.02M | 1.47M |
| Rev Growth | +16.3% | -0.5% | +13.7% |
| Debt/Equity | 1.56 | 1.35 | 1.56 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |